Prolomet xp
Reading File
Searching for information on Prolomet XP now.
search_medical_text
Prolomet XP metoprolol succinate extended release
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Page 104
search_medical_text
metoprolol succinate XR indications dosage pharmacology
Management of Patients with Chronic Coronary Disease
Page 54
GradeResponse
GradeResponse
Prolomet XP is a brand name (manufactured by Sun Pharma, primarily marketed in India) for Metoprolol Succinate Extended-Release (XR/XL). Here is a comprehensive overview:
Prolomet XP — Metoprolol Succinate Extended Release
Drug Class
- Cardioselective beta-1 adrenergic blocker (beta-blocker)
- Extended-release formulation providing once-daily dosing
Available Strengths
| Strength | Common Use |
|---|---|
| 25 mg XP | Heart failure, hypertension (low-dose initiation) |
| 50 mg XP | Hypertension, angina, heart failure |
| 100 mg XP | Hypertension, angina, post-MI |
| 200 mg XP | Higher-dose requirements |
Indications
- Hypertension — reduces blood pressure via decreased cardiac output and renin release
- Chronic Heart Failure (HFrEF) — reduces mortality; started at low dose (12.5–25 mg/day) and titrated up
- Stable Angina Pectoris — reduces myocardial oxygen demand
- Post-Myocardial Infarction — reduces reinfarction and mortality
- Rate control in Atrial Fibrillation/Flutter
- Symptomatic relief in Hyperthyroidism (adjunct)
Per the ACC/AHA Guidelines and the POISE trial (Lancet 2008, p. 1839), extended-release metoprolol succinate is the preferred beta-blocker formulation for heart failure due to its consistent plasma levels and superior tolerability over immediate-release metoprolol tartrate.
Dosing
| Indication | Starting Dose | Target/Maintenance Dose |
|---|---|---|
| Hypertension | 25–50 mg once daily | 50–200 mg once daily |
| Chronic Heart Failure | 12.5–25 mg once daily | Up to 200 mg once daily (titrate slowly over weeks) |
| Angina | 100 mg once daily | 100–200 mg once daily |
| Post-MI | 25–50 mg once daily | 100–200 mg once daily |
- Per ACC/AHA Chronic Coronary Disease Guidelines (p. 54), target dose for metoprolol succinate in heart failure is 200 mg/day, titrated from a starting dose of 25 mg/day.
- Tablets should be swallowed whole — not crushed or chewed (destroys extended-release matrix).
- Taken with or without food, preferably at the same time each day.
Mechanism of Action
- Selectively blocks β1-adrenergic receptors in the heart
- Reduces heart rate, myocardial contractility, and blood pressure
- At higher doses, some β2 blockade may occur (caution in asthma/COPD)
Contraindications
- Cardiogenic shock
- Decompensated heart failure (acute phase)
- Sick sinus syndrome or high-degree AV block (without pacemaker)
- Severe bradycardia (HR < 45–50 bpm)
- Severe reactive airway disease (relative)
- Hypersensitivity to metoprolol or other beta-blockers
Key Side Effects
| System | Side Effects |
|---|---|
| Cardiovascular | Bradycardia, hypotension, AV block |
| CNS | Fatigue, dizziness, sleep disturbances, depression |
| Respiratory | Bronchospasm (dose-dependent, less than non-selective agents) |
| Metabolic | Masks hypoglycemia symptoms in diabetics |
| Sexual | Erectile dysfunction |
Important Precautions
- Do not abruptly discontinue — taper over 1–2 weeks to avoid rebound hypertension, angina, or MI
- Use cautiously in diabetes (masks hypoglycemia signs except sweating)
- Use cautiously in peripheral vascular disease
- Monitor renal/hepatic function (hepatic metabolism via CYP2D6)
Drug Interactions
- Verapamil/Diltiazem — additive bradycardia and AV block risk
- Clonidine — abrupt clonidine withdrawal can cause hypertensive crisis; discontinue beta-blocker first
- CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) — increase metoprolol plasma levels
- NSAIDs — may blunt antihypertensive effect
- Insulin/oral hypoglycemics — may mask hypoglycemic symptoms
Prolomet XP vs. Prolomet (Immediate Release)
| Feature | Prolomet (Tartrate IR) | Prolomet XP (Succinate ER) |
|---|---|---|
| Salt form | Metoprolol tartrate | Metoprolol succinate |
| Dosing frequency | Twice daily | Once daily |
| Peak plasma fluctuation | High | Low (smoother) |
| Preferred in heart failure | No | Yes |
| Bioavailability consistency | Variable | More consistent |
Bottom line: Prolomet XP (metoprolol succinate ER) offers the pharmacological advantage of stable plasma drug levels with once-daily dosing, making it preferred over IR formulations particularly in heart failure and hypertension management.
This is a shared conversation. Sign in to Orris to start your own chat.